Sarcomas | Specialty

The OncLive Sarcomas/TGCT condition center page is a comprehensive resource for clinical news and expert insights on tenosynovial giant cell tumor (TGCT), soft tissue sarcoma, gastrointestinal stromal tumor, Ewing sarcoma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in sarcomas and TGCT.

SON-1010 Plus Trabectedin Completes First Safety Review in Advanced Leiomyosarcoma/Liposarcoma

March 26th 2025

Findings from the safety review of SON-1010 plus trabectedin in patients with advanced leiomyosarcoma or liposarcoma were positive.

Nivolumab Plus Sunitinib Hits Primary End Point in Advanced Bone Sarcoma IMMUNOSARC Study

March 25th 2025

Nivolumab plus sunitinib displayed early-phase efficacy in advanced bone sarcoma.

Dr Randall on a Bioengineered Bone Marrow Matrix to Explore Osteosarcoma Progression and Metastasis

March 24th 2025

R. Lor Randall, MD, FACS, discusses the application of a bioengineered bone marrow matrix as a three-dimensional model to analyze osteosarcoma cell behavior under varying oxygen tensions.

Eribulin and Trabectedin Yield Comparable Real-World OS Outcomes in Advanced Liposarcoma

March 24th 2025

A real-world study showed OS outcomes with eribulin similar to those with trabectedin in doxorubicin-pretreated patients with advanced liposarcoma.

Bioengineered Bone Marrow Model Reveals Potential New Strategies for Osteosarcoma Metastasis Control

March 21st 2025

R. Lor Randall, MD, FACS, discusses the development of a bone marrow matrix to study osteosarcoma and the model’s mechanisms of metastasis control.

Dr Randall on Factors Influencing the Choice Between Systemic Therapy and Surgery in TGCT

March 20th 2025

R. Lor Randall, MD, FACS, discusses how to select between vimseltinib, pexidartinib, and surgery for patients with tenosynovial giant cell tumor.

Five Under 5: Top Oncology Videos for the Week of 3/2

March 9th 2025

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Vimseltinib Stands Out as An Alternative to Surgery for Select Patients With Diffuse TGCT

March 6th 2025

R. Lor Randall, MD, FACS, discusses the significance of the FDA approval of vimseltinib for patients with symptomatic TGCT.

Data Compilation Highlights Potential of SON-1010 to Enhance Therapeutic Efficacy in Solid Tumors

March 5th 2025

SON-1010 is being investigated for its potential to improve outcomes in solid tumors.

OncLive’s FDA Approval Report: The Regulatory Rundown for February 2025

March 1st 2025

Here is your snapshot for all therapeutic options that were approved by the FDA in February 2025 spanning tumor types.

Dr Somaiah on the Role of Chemotherapy in Sarcomas

February 26th 2025

Neeta Somaiah, MD, discusses chemotherapy as the current mainstay of treatment in sarcoma subtypes and the emergence of immunotherapies in the space.

OH2 Demonstrates Tolerability and Combination Activity in Advanced Sarcoma

February 25th 2025

OH2 monotherapy was safe and treatment with the agent led to responses in combination with HX008 in locally advanced or metastatic sarcoma.

Future Perspectives on TCR Therapies for Sarcomas and Other Solid Tumors

February 25th 2025

A panelist discusses how T-cell receptor (TCR) therapies are likely to evolve through innovations such as allogeneic approaches, enhanced manufacturing processes, identification of new target antigens, and potential combinations with other immunotherapies, which could expand their applicability across multiple sarcoma subtypes and other solid tumors while improving accessibility and efficacy.

Comparing Afami-Cel Outcomes With Chemotherapy and Other Treatment Options

February 25th 2025

A panelist discusses how afamitresgene autoleucel (afami-cel) has shown encouraging response rates and durability of response in a heavily pretreated population where standard chemotherapy typically yields limited benefit, though direct comparisons are challenging because of the lack of randomized trials and the distinct patient populations treated with different therapeutic approaches.

Dr Randall on the Utility of Intraoperative Peripheral Margin Assessment in Soft Tissue Sarcomas

February 24th 2025

R. Lor Randall, MD, FACS, discusses the utility of routine intraoperative frozen margin assessment in soft tissue sarcoma.

Efineptakin Alfa Represents Potentially Effective Option in Kaposi Sarcoma

February 24th 2025

The long-acting IL-7 agent efineptakin alfa was tolerable and led to responses in patients with Kaposi sarcoma, including in HIV-associated disease.

Global Survey Outlines Optimal Population for Surgical Treatment of Proximal Femur Metastases

February 19th 2025

R. Lor Randall, MD, FACS, discusses the enrollment criteria for a trial investigating surgical outcomes in patients with proximal femur metastases.

Biomarker-Driven Research Accelerates Drug Discovery and Precision Medicine Approaches in Sarcoma

February 18th 2025

Neeta Somaiah, MD, highlights the evolving sarcoma treatment paradigm within the past 5 years, including the FDA approval of afamitresgene autoleucel.

Logistical Considerations for Delivering TCR Therapy to Patients

February 18th 2025

A panelist discusses how the logistical challenges of delivering T-cell receptor (TCR) therapy include coordinating lymphodepletion timing, managing the multiweek manufacturing process, ensuring proper handling and chain of custody of cellular products, and requiring specialized treatment centers with cell therapy expertise and infrastructure.

Comparing Postinfusion Challenges in TCR Therapy and Standard-of-Care Regimens

February 18th 2025

A panelist discusses how the postinfusion challenges with afamitresgene autoleucel (afami-cel), such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome, are generally manageable and time limited compared with the chronic cumulative toxicities seen with conventional chemotherapy regimens, though careful monitoring and prompt intervention remain essential.